Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
MetadataShow full item record
AbstractHepatitis B virus (HBV) chronically infects over 250 million people worldwide and causes nearly 1 million deaths per year due to cirrhosis and liver cancer. Approved treatments for chronic infection include injectable type-I interferons and nucleos(t)ide reverse transcriptase inhibitors. A small minority of patients achieve seroclearance after treatment with type-I interferons, defined as sustained absence of detectable HBV DNA and surface antigen (HBsAg) antigenemia. However, type-I interferons cause significant side effects, are costly, must be administered for months, and most patients have viral rebound or non-response. Nucleos(t)ide reverse transcriptase inhibitors reduce HBV viral load and improve liver-related outcomes, but do not lower HBsAg levels or impart seroclearance. Thus, new therapeutics are urgently needed. Lambda interferons (IFNLs) have been tested as an alternative strategy to stimulate host antiviral pathways to treat HBV infection. IFNLs comprise an evolutionarily conserved innate immune pathway and have cell-type specific activity on hepatocytes, other epithelial cells found at mucosal surfaces, and some immune cells due to restricted cellular expression of the IFNL receptor. This article will review work that examined expression of IFNLs during acute and chronic HBV infection, the impact of IFNLs on HBV replication in vitro and in vivo, the association of polymorphisms in IFNL genes with clinical outcomes, and the therapeutic evaluation of IFNLs for the treatment of chronic HBV infection. © 2021 by the authors.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16124
- Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.
- Authors: Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F
- Issue date: 2017 May
- Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
- Authors: Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF
- Issue date: 2020 Jun
- Immunopathogenesis of Hepatitis B Virus.
- Authors: Tseng TC, Huang LR
- Issue date: 2017 Nov 16
- Management of viral hepatitis B.
- Authors: Pramoolsinsup C
- Issue date: 2002 Feb
- Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes.
- Authors: Murreddu MG, Suresh M, Gudima SO, Menne S
- Issue date: 2017